ARROWHEAD PHARMACEUTICALS, INC. Income (Loss) from Equity Method Investments
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Income (Loss) from Equity Method Investments of -$2.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from equity method investments for the quarter ending 2026-06-30 was -$2.47M.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from equity method investments for the quarter ending 2026-03-31 was -$6.72M.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from equity method investments for the quarter ending 2025-06-30 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from equity method investments for the quarter ending 2025-03-31 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from equity method investments for fiscal 2014 was -$78.87K.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from equity method investments for fiscal 2013 was -$641.14K.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from equity method investments for fiscal 2012 was -$240.15K.
- ARROWHEAD PHARMACEUTICALS, INC. income (loss) from equity method investments for fiscal 2011 was -$163.18K.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month | Income (Loss) from Equity Method Investments 98 month | Income (Loss) from Equity Method Investments 101 month | Income (Loss) from Equity Method Investments 104 month | Income (Loss) from Equity Method Investments 107 month | Income (Loss) from Equity Method Investments 110 month | Income (Loss) from Equity Method Investments 113 month | Income (Loss) from Equity Method Investments 116 month | Income (Loss) from Equity Method Investments 119 month | Income (Loss) from Equity Method Investments 122 month | Income (Loss) from Equity Method Investments 125 month | Income (Loss) from Equity Method Investments 128 month | Income (Loss) from Equity Method Investments 131 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$2.47M 10-Q · filed 2026-08-04 | -$9.19M derived: sum of 2 quarters · filed 2026-08-04 | -$9.19M 10-Q · filed 2026-08-04 | |||||||||||||
| 2026-03-31 | -$6.72M 10-Q · filed 2026-05-07 | -$6.72M 10-Q · filed 2026-05-07 | ||||||||||||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-04 | $0.00 derived: sum of 2 quarters · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | |||||||||||||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 10-Q · filed 2026-05-07 | ||||||||||||||
| 2014-09-30 | -$9.52K derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-14 | $69.18K derived: sum of 2 quarters · filed 2016-12-14 | $59.58K derived: sum of 3 quarters · filed 2016-12-14 | -$78.87K 10-K · filed 2016-12-14 | ||||||||||||
| 2014-06-30 | $78.70K 10-Q · filed 2015-08-04 | $69.11K derived: sum of 2 quarters · filed 2015-08-04 | -$69.35K 10-Q · filed 2015-08-04 | -$329.79K derived: sum of 4 quarters · filed 2015-12-14 | ||||||||||||
| 2014-03-31 | -$9.60K 10-Q · filed 2015-05-11 | -$148.05K 10-Q · filed 2015-05-11 | -$408.50K derived: sum of 3 quarters · filed 2015-12-14 | -$568.02K derived: sum of 4 quarters · filed 2015-12-14 | -$1.75M 10-Q · filed 2014-05-06 | |||||||||||
| 2013-12-31 | -$138.46K 10-Q · filed 2015-02-09 | -$398.90K derived: sum of 2 quarters · filed 2015-12-14 | -$558.43K derived: sum of 3 quarters · filed 2015-12-14 | -$716.04K derived: sum of 4 quarters · filed 2015-12-14 | -$1.74M 10-Q · filed 2014-02-04 | |||||||||||
| 2013-09-30 | -$260.44K derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-14 | -$419.97K derived: sum of 2 quarters · filed 2015-12-14 | -$577.58K derived: sum of 3 quarters · filed 2015-12-14 | -$641.14K 10-K · filed 2015-12-14 | -$1.60M 10-K · filed 2013-12-18 | |||||||||||
| 2013-06-30 | -$159.53K 10-Q · filed 2014-08-12 | -$317.14K derived: sum of 2 quarters · filed 2014-08-12 | -$380.70K 10-Q · filed 2014-08-12 | -$415.49K derived: sum of 4 quarters · filed 2014-11-25 | -$1.34M 10-Q · filed 2013-08-07 | |||||||||||
| 2013-03-31 | -$157.61K 10-Q · filed 2014-05-06 | -$221.17K 10-Q · filed 2014-05-06 | -$255.96K derived: sum of 3 quarters · filed 2014-11-25 | -$290.54K derived: sum of 4 quarters · filed 2014-11-25 | -$1.18M 10-Q · filed 2013-05-09 | |||||||||||
| 2012-12-31 | -$63.56K 10-Q · filed 2014-02-04 | -$98.35K derived: sum of 2 quarters · filed 2014-11-25 | -$132.92K derived: sum of 3 quarters · filed 2014-11-25 | -$197.18K derived: sum of 4 quarters · filed 2014-11-25 | -$1.03M 10-Q · filed 2013-02-13 | |||||||||||
| 2012-09-30 | -$34.79K derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-25 | -$69.37K derived: sum of 2 quarters · filed 2014-11-25 | -$133.63K derived: sum of 3 quarters · filed 2014-11-25 | -$240.15K 10-K · filed 2014-11-25 | -$963.41K 10-K · filed 2012-12-28 | |||||||||||
| 2012-06-30 | -$34.57K 10-Q · filed 2013-08-07 | -$98.83K derived: sum of 2 quarters · filed 2013-08-07 | -$205.36K 10-Q · filed 2013-08-07 | -$272.17K derived: sum of 4 quarters · filed 2013-08-07 | -$928.61K 10-Q · filed 2012-08-13 | |||||||||||
| 2012-03-31 | -$64.26K 10-Q · filed 2013-05-09 | -$170.79K 10-Q · filed 2013-05-09 | -$237.60K derived: sum of 3 quarters · filed 2013-05-09 | -$307.97K derived: sum of 4 quarters · filed 2013-05-09 | -$894.04K 10-Q · filed 2012-05-08 | |||||||||||
| 2011-12-31 | -$106.53K 10-Q · filed 2013-02-13 | -$173.34K derived: sum of 2 quarters · filed 2013-02-13 | -$243.71K derived: sum of 3 quarters · filed 2013-02-13 | -$318.53K derived: sum of 4 quarters · filed 2013-02-13 | -$829.78K 10-Q · filed 2012-02-09 | |||||||||||
| 2011-09-30 | -$66.81K derived: 10-K 12 month − 10-Q 9 month · filed 2012-12-28 | -$137.18K derived: sum of 2 quarters · filed 2012-12-28 | -$212.01K derived: sum of 3 quarters · filed 2012-12-28 | -$163.18K 10-K · filed 2012-12-28 | -$723.25K 10-K · filed 2011-12-20 | |||||||||||
| 2011-06-30 | -$70.37K 10-Q · filed 2012-08-13 | -$145.19K derived: sum of 2 quarters · filed 2012-08-13 | -$96.37K 10-Q · filed 2012-08-13 | -$150.18K derived: sum of 4 quarters · filed 2012-08-13 | -$656.44K 10-Q · filed 2011-08-08 | |||||||||||
| 2011-03-31 | -$74.83K 10-Q · filed 2012-05-08 | -$26.00K 10-Q · filed 2012-05-08 | -$79.81K derived: sum of 3 quarters · filed 2012-05-08 | -$146.30K derived: sum of 4 quarters · filed 2012-05-08 | ||||||||||||
| 2010-12-31 | $48.83K 10-Q · filed 2012-02-09 | -$4.99K derived: sum of 2 quarters · filed 2012-02-09 | -$71.48K derived: sum of 3 quarters · filed 2012-02-09 | |||||||||||||
| 2010-09-30 | -$53.81K derived: 10-K 12 month − 10-Q 9 month · filed 2011-12-20 | -$120.30K derived: sum of 2 quarters · filed 2011-12-20 | -$219.54K 10-K · filed 2011-12-20 | |||||||||||||
| 2010-06-30 | -$66.49K 10-Q · filed 2011-08-08 | -$165.73K 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |